All In Biotech

Drug Trial Radar · NCT05519072

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA Treatment of Overactive Bladder: a Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Aug 16, 2022

Primary completion

Aug 16, 2024

Study completion Aug 16, 2024

Sponsor

Lead sponsor
Atlantic Health SystemAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Columbia University
First posted
Aug 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to show that lack of antibiotic prophylaxis to those undergoing bladder Botox injections is not significantly inferior to administering prophylaxis. By proving this, the investigators aim to decrease antibiotic use in this setting to combat the growing issue of antibiotic resistance. Participants will be randomized to antibiotic or no treatment arm. Those randomized to the treatment arm will receive oral antibiotics for 2 days pre-treatment, on the treatment day, and 2 days post-treatment. Participants will return for a follow up appointment approximately 2 weeks after treatment to assess for urinary tract infection (UTI) symptoms. They will be called again at 6 weeks for follow up.

Conditions

  • Antibiotic Prophylaxis

Interventions

  • NitrofurantoinDrug

    For those randomized to the treatment arm, antibiotics will be prescribed at the discretion of the ordering physician. They will be prescribed only in oral form and in accordance with the patient's allergy profile.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urinary tract infectionsTime frame: 2 weeks post-procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Atlantic Health

    Morristown, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.